选择性β受体阻滞剂摄入对上皮性卵巢癌患者生存无影响
该研究回顾性分析1999至2014年两家三级妇科肿瘤中心连续收治的801例原发上皮性卵巢癌患者,其中141例(17.6%)同时使用选择性β受体阻滞剂。结果显示,使用与未使用选择性β受体阻滞剂两组患者的无进展生存期和总生存期均无显著差异,多因素分析也未发现选择性β受体阻滞剂摄入与预后相关。
要点
- 801例上皮性卵巢癌患者中141例(17.6%)使用选择性β受体阻滞剂。
- 使用与未使用选择性β受体阻滞剂两组无进展生存期(27个月 vs 24个月,p=0.40)和总生存期(56个月 vs 44个月,p=0.15)无显著差异。
- 多因素分析未发现选择性β受体阻滞剂摄入与预后相关。
核心结论
- 选择性β受体阻滞剂摄入不影响上皮性卵巢癌患者的预后。
研究设计与样本
- 研究纳入1999至2014年在两家三级妇科肿瘤中心连续收治的所有原发上皮性卵巢癌患者,用药情况通过病历回顾性分析。
主要发现
- 研究队列共801例患者,其中141例(17.6%)接受选择性β受体阻滞剂。
- 未使用选择性β受体阻滞剂患者的中位年龄为56岁(范围19-90岁),使用选择性β受体阻滞剂患者为64岁(范围41-84岁),p<0.001。
- 使用选择性β受体阻滞剂患者中63.8%实现肿瘤完全切除,未使用者为74.2%,p=0.012。
- 未使用选择性β受体阻滞剂患者术后严重并发症(Clavien-Dindo分类)较少(18.8% vs 29.0%,p=0.003)。
- 使用与未使用选择性β受体阻滞剂两组无进展生存期分别为24个月和27个月(p=0.40),总生存期分别为44个月和56个月(p=0.15),均无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Some authors have claimed a significant impact of β-blocking agents on outcome in epithelial ovarian cancer (EOC). This study investigated the impact of concurrent medication with selective beta blockers (SBB) in patients undergoing primary treatment for EOC. METHODS: The study included all consecutive patients with primary EOC treated in two tertiary gynecological-oncologic units between 1999 and 2014. Medication was retrospectively analyzed by chart review. RESULTS: The study cohort comprised 801 patients, of whom 141 (17.6%) had received SBB. Median age of patients without SBB medication was 56years (range: 19-90years) and 64years (range: 41-84years) in patients taking SBB (p<0.001). The main prognostic factor FIGO stage did not differ between both cohorts. 63.8% of patients taking SBB underwent complete tumor resection compared to 74.2% of patients without SBB (p=0.012). Patients without SBB experienced less severe post-operative complications according to the Clavien-Dindo classification (18.8% vs 29.0%; p=0.003). Between the both groups without and with SBB intake, PFS and OS did not differ significantly (PFS: 27months and 24months, p=0.40; OS: 56months and 44, p=0.15). Multivariate analyses did not yield any association between SBB intake and prognosis but confirmed well-known prognostic factors. CONCLUSIONS: Intake of selective β-blockers did not influence the prognosis of patients with EOC.
引用
- Heitz F, Hengsbach A, Harter P, et al. Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer. Gynecol Oncol. 2016. PMID: 27863705. doi:10.1016/j.ygyno.2016.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。